Compare Stocks

→ At first glance, this chart looks like nonsense… (From The TradingPub) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBLI Cleveland BioLabs	$0.00	$3.19	$1.62 ▼ $10.97	$11K	0.7	271,922 shs	21,109 shs
CYAD Celyad Oncology	$0.60	$0.67	$0.46 ▼ $3.07	$15.91M	N/A	N/A	3,009 shs
EMMA Emmaus Life Sciences	$0.09	$0.11	$0.05 ▼ $0.34	$5.70M	1.61	4,134 shs	33 shs
LACQ Leisure Acquisition	$0.54 -5.3%	$13.67	$10.11 ▼ $23.99	$3.37M	-0.3	5,426 shs	53,698 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBLI Cleveland BioLabs	0.00%	+16.67%	+16.67%	+16.67%	-96.83%
CYAD Celyad Oncology	0.00%	0.00%	0.00%	0.00%	-6.25%
EMMA Emmaus Life Sciences	-0.01%	-12.29%	-10.58%	-3.36%	-72.09%
LACQ Leisure Acquisition	0.00%	-23.35%	-28.54%	-49.91%	-84.44%

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBLI Cleveland BioLabs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LACQ Leisure Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBLI Cleveland BioLabs	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A
LACQ Leisure Acquisition	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBLI Cleveland BioLabs	$260K	0.04	N/A	N/A	$0.87 per share	0.00
CYAD Celyad Oncology	$110K	144.65	N/A	N/A	$0.20 per share	3.00
EMMA Emmaus Life Sciences	$18.39M	0.31	N/A	N/A	($0.69) per share	-0.13
LACQ Leisure Acquisition	N/A	N/A	$0.03 per share	20.03	($0.19) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBLI Cleveland BioLabs	-$2.40M	N/A	0.00	∞	N/A	N/A	-32.84%	-31.29%	N/A
CYAD Celyad Oncology	-$9.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	-$10.62M	-$0.10	N/A	∞	N/A	-16.66%	N/A	-9.73%	N/A
LACQ Leisure Acquisition	$4.31M	N/A	0.00	∞	N/A	N/A	30.17%	6.14%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBLI Cleveland BioLabs	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A	N/A
LACQ Leisure Acquisition	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBLI Cleveland BioLabs	N/A	45.93	45.93
CYAD Celyad Oncology	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	0.15	0.12
LACQ Leisure Acquisition	0.24	0.71	0.71

Ownership

Institutional Ownership

Company	Institutional Ownership
CBLI Cleveland BioLabs	5.09%
CYAD Celyad Oncology	N/A
EMMA Emmaus Life Sciences	7.42%
LACQ Leisure Acquisition	56.67%

Insider Ownership

Company	Insider Ownership
CBLI Cleveland BioLabs	1.03%
CYAD Celyad Oncology	0.94%
EMMA Emmaus Life Sciences	35.00%
LACQ Leisure Acquisition	39.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CBLI Cleveland BioLabs	4	15.48 million	N/A	Not Optionable
CYAD Celyad Oncology	95	26.52 million	26.28 million	Not Optionable
EMMA Emmaus Life Sciences	54	61.85 million	40.20 million	Not Optionable
LACQ Leisure Acquisition	N/A	6.22 million	N/A	Not Optionable

CYAD, EMMA, LACQ, and CBLI Headlines

Source	Headline
	Gateshead leisure centres to receive energy efficiency grant worth millions to help secure future itv.com - April 23 at 2:45 AM
	This Coastal Town in Portugal Is a Hidden Gem — With Scenic Beaches, Beautiful Architecture, and Few Crowds travelandleisure.com - April 10 at 6:48 PM
	23 Affordable Beach Vacations Around the World travelandleisure.com - April 3 at 1:19 PM
	MRC Global Announces Agreement with Engine Capital and Appointment of Daniel Silvers to the Board of Directors finance.yahoo.com - April 2 at 7:16 AM
	Travelers Are Forgoing Luxury for Nature-focused Trips That Push Their Physical (and Emotional) Limits — Here's Why travelandleisure.com - March 31 at 7:55 AM
	Council to spend £1m on leisure centre solar panels bbc.com - March 18 at 7:39 PM
	Wanda S. Radetti travelandleisure.com - February 29 at 8:07 AM
	Allie Almario travelandleisure.com - February 29 at 8:07 AM
	Craig Beal travelandleisure.com - February 27 at 10:36 AM
	The 6 Best Snowboard Bags of 2024, Tested and Reviewed travelandleisure.com - February 25 at 2:55 PM
	David Lowy travelandleisure.com - February 24 at 7:40 AM
	Christos Stergiou travelandleisure.com - February 24 at 7:40 AM
	Cassandra Bookholder travelandleisure.com - February 24 at 2:02 AM
	Gaming & Leisure Properties Inc. wsj.com - January 23 at 2:50 PM
	The 9 Most Comfortable Flats of 2024, Tested and Reviewed travelandleisure.com - January 5 at 11:07 PM
	The 8 Best Peacoats of 2024, Tested and Reviewed travelandleisure.com - January 3 at 8:44 PM
	15 Best Places to Travel in February 2024 travelandleisure.com - December 14 at 12:28 PM
	This May Be the Most Photogenic City in Europe — With Scenic Canals, Cobblestone Streets, and Twinkling Christmas Markets travelandleisure.com - December 13 at 3:40 PM
	This Is the Best Time to Renew Global Entry — and How to Do It travelandleisure.com - December 4 at 10:16 PM
	This Japanese Mountain Town Is Known for Making Beautiful Lacquerware — and the Tradition Goes Back Centuries travelandleisure.com - November 6 at 8:09 AM
	United Will Change Its Boarding Process This Month travelandleisure.com - November 6 at 8:09 AM
	This Is the World's Best Bar for 2023 travelandleisure.com - November 5 at 2:34 PM
	This New Florida Glamping Spot Offers Dome Stays — Each With 13-foot Window Ceilings travelandleisure.com - October 23 at 3:19 PM
	Passport Processing Times Are Down — How Long It Will Take to Renew travelandleisure.com - October 23 at 3:19 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cleveland BioLabs

NASDAQ:CBLI

Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Celyad Oncology

NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Emmaus Life Sciences

OTCMKTS:EMMA

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Leisure Acquisition

NASDAQ:LACQ

Leisure Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination. The company was incorporated in 2017 and is based in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial